|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01801 INNOVENT BIO
Nominal 
110.800 +1.000 (+0.911%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 8,617,801 | 44.762% | 13,041,523 | 9,421,888 | 6,206,070 | 4,556,380 |
| Cost of Sales | (1,296,044) | 55.503% | (1,756,019) | (1,510,210) | (1,136,266) | (930,990) |
| Gross Profit | 7,321,757 | 43.013% | 11,285,504 | 7,911,678 | 5,069,804 | 3,625,390 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (41,900) | 77.829% | (96,788) | (41,009) | 0 | 0 | |
| Profit / (Loss) before Taxation | 1,611,663 | 79.649% | 838,924 | (78,621) | (1,144,411) | (2,170,469) | |
| Taxation | (358,521) | 470.930% | (25,359) | (16,010) | 116,498 | (8,801) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,253,142 | 50.199% | 813,565 | (94,631) | (1,027,913) | (2,179,270) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (315,334) | 144.239% | (359,088) | (355,807) | (354,213) | (87,839) |
| Depreciation & Amortisation | 331,672 | 24.693% | 601,317 | 419,768 | 250,822 | 177,768 |
| Directors' Emoluments | -- | -- | -- | 196,113 | 171,327 | 171,378 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 73.000 | 43.137% | 48.000 | -6.000 | -66.000 | -146.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 5.962 | 0.791 | 0.095 | (1.288) |
| NBV per share ($) | 11.935 | -- | 11.159 | 8.008 | 7.724 | 6.993 |
| Remarks: | Real time quote last updated: 27/08/2026 09:23 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,253,142 |
| %Change | 50.199% |
| EPS / (LPS) | RMB 0.730 |
| NBV Per Share (¥) | RMB 11.935 |